Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F McDermott

Showing results (111-120 of 227) with videos related to

Pageof 23
Sort By:
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM<sup>SM</sup> registryBrendan Curti, Gregory A Daniels, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanomaKevin B Kim, Jeffrey A Sosman, John P Fruehauf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyDavid F McDermott, Jeffrey A Sosman, Mario Sznol, et al.
Melanoma Research|September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanomaShalin Shah, Jason J Luke, Heather A Jacene, et al.
BJU International|January 20, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisDebra Josephs, Thomas E Hutson, Charles L Cowey, et al.
The Lancet. Oncology|February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Journal for Immunotherapy of Cancer|March 19, 2022
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinomaRobert J Motzer, Toni K Choueiri, David F McDermott, et al.
The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Pageof 23

Showing results (111-120 of 227) with videos related to

Sort By:
Pageof 23
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Journal for Immunotherapy of Cancer|December 20, 2017
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM<sup>SM</sup> registryBrendan Curti, Gregory A Daniels, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2011
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanomaKevin B Kim, Jeffrey A Sosman, John P Fruehauf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyDavid F McDermott, Jeffrey A Sosman, Mario Sznol, et al.
Melanoma Research|September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanomaShalin Shah, Jason J Luke, Heather A Jacene, et al.
BJU International|January 20, 2011
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysisDebra Josephs, Thomas E Hutson, Charles L Cowey, et al.
The Lancet. Oncology|February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialMichael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Journal for Immunotherapy of Cancer|March 19, 2022
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinomaRobert J Motzer, Toni K Choueiri, David F McDermott, et al.
The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Pageof 23